tiprankstipranks
Trending News
More News >
Arcellx, Inc. (ACLX)
:ACLX
US Market

Arcellx Inc (ACLX) Stock Forecast & Price Target

Compare
239 Followers
See the Price Targets and Ratings of:

ACLX Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Arcellx
Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACLX Stock 12 Month Forecast

Average Price Target

$111.00
▲(71.38%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Arcellx Inc in the last 3 months. The average price target is $111.00 with a high forecast of $121.00 and a low forecast of $93.00. The average price target represents a 71.38% change from the last price of $64.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","122":"$122","68.75":"$68.8","86.5":"$86.5","104.25":"$104.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$93.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,68.75,86.5,104.25,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.93,66.47384615384615,71.0176923076923,75.56153846153846,80.10538461538462,84.64923076923077,89.19307692307692,93.73692307692308,98.28076923076924,102.82461538461538,107.36846153846153,111.91230769230769,116.45615384615385,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.93,65.70461538461538,69.47923076923077,73.25384615384615,77.02846153846154,80.80307692307693,84.5776923076923,88.35230769230769,92.12692307692308,95.90153846153846,99.67615384615385,103.45076923076923,107.22538461538463,{"y":111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.93,64.32,66.71,69.1,71.49,73.88,76.27,78.66,81.05,83.44,85.83,88.22,90.61,{"y":93,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$121.00Average Price Target$111.00Lowest Price Target$93.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ACLX
TipRanks AITipRanks
Not Ranked
TipRanks
$67
Hold
3.44%
Upside
Reiterated
06/27/25
Arcellx Inc's overall score is driven by promising pipeline developments and strategic partnerships, highlighted by positive clinical trial results. However, financial challenges and negative earnings weigh down the score. The technical analysis shows a stable trend, but valuation remains a concern with a negative P/E ratio.
Citi
$110
Buy
69.83%
Upside
Initiated
06/18/25
Arcellx initiated with a Buy at CitiArcellx initiated with a Buy at Citi
Barclays Analyst forecast on ACLX
Peter LawsonBarclays
Barclays
$115
Buy
77.55%
Upside
Reiterated
06/17/25
Analysts Offer Insights on Healthcare Companies: Demant (Other OTC: WILLF), Moderna (NASDAQ: MRNA) and Arcellx Inc (NASDAQ: ACLX)
William Blair Analyst forecast on ACLX
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
06/16/25
Arcellx Inc's Promising Market Position and Growth Potential in Multiple Myeloma Therapy
Piper Sandler Analyst forecast on ACLX
Biren AminPiper Sandler
Piper Sandler
$115
Buy
77.55%
Upside
Reiterated
06/16/25
Piper Sandler Remains a Buy on Arcellx Inc (ACLX)
TD Cowen
Buy
Reiterated
06/16/25
TD Cowen Remains a Buy on Arcellx Inc (ACLX)
Needham Analyst forecast on ACLX
Gil BlumNeedham
Needham
$105
Buy
62.11%
Upside
Reiterated
06/16/25
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning
H.C. Wainwright Analyst forecast on ACLX
Emily BodnarH.C. Wainwright
H.C. Wainwright
$115
Buy
77.55%
Upside
Reiterated
06/16/25
Arcellx Inc's Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
Morgan Stanley Analyst forecast on ACLX
Judah FrommerMorgan Stanley
Morgan Stanley
$111
Buy
71.38%
Upside
Reiterated
06/15/25
Promising Potential of Arcellx Inc's Anito-cel Therapy Drives Buy Rating
Bank of America Securities Analyst forecast on ACLX
Jason GerberryBank of America Securities
Bank of America Securities
$112
Buy
72.92%
Upside
Reiterated
06/13/25
Arcellx Inc's Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential
Canaccord Genuity Analyst forecast on ACLX
John NewmanCanaccord Genuity
Canaccord Genuity
$121
Buy
86.81%
Upside
Reiterated
06/13/25
Arcellx Inc's Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
Evercore ISI Analyst forecast on ACLX
Cory KasimovEvercore ISI
Evercore ISI
$115
Buy
77.55%
Upside
Reiterated
05/15/25
Evercore ISI Sticks to Their Buy Rating for Arcellx Inc (ACLX)
Scotiabank Analyst forecast on ACLX
George FarmerScotiabank
Scotiabank
$93
Buy
43.58%
Upside
Reiterated
05/15/25
Scotiabank Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Truist Financial Analyst forecast on ACLX
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
05/15/25
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Lucid Diagnostics (NASDAQ: LUCD) and Arcellx Inc (NASDAQ: ACLX)
Guggenheim Analyst forecast on ACLX
Unknown AnalystGuggenheim
Not Ranked
Guggenheim
$120
Buy
85.27%
Upside
Reiterated
05/15/25
Anito-Cel’s best-in-class safety profile continues; we remain Buy rated, PT $120.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ACLX
TipRanks AITipRanks
Not Ranked
TipRanks
$67
Hold
3.44%
Upside
Reiterated
06/27/25
Arcellx Inc's overall score is driven by promising pipeline developments and strategic partnerships, highlighted by positive clinical trial results. However, financial challenges and negative earnings weigh down the score. The technical analysis shows a stable trend, but valuation remains a concern with a negative P/E ratio.
Citi
$110
Buy
69.83%
Upside
Initiated
06/18/25
Arcellx initiated with a Buy at CitiArcellx initiated with a Buy at Citi
Barclays Analyst forecast on ACLX
Peter LawsonBarclays
Barclays
$115
Buy
77.55%
Upside
Reiterated
06/17/25
Analysts Offer Insights on Healthcare Companies: Demant (Other OTC: WILLF), Moderna (NASDAQ: MRNA) and Arcellx Inc (NASDAQ: ACLX)
William Blair Analyst forecast on ACLX
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
06/16/25
Arcellx Inc's Promising Market Position and Growth Potential in Multiple Myeloma Therapy
Piper Sandler Analyst forecast on ACLX
Biren AminPiper Sandler
Piper Sandler
$115
Buy
77.55%
Upside
Reiterated
06/16/25
Piper Sandler Remains a Buy on Arcellx Inc (ACLX)
TD Cowen
Buy
Reiterated
06/16/25
TD Cowen Remains a Buy on Arcellx Inc (ACLX)
Needham Analyst forecast on ACLX
Gil BlumNeedham
Needham
$105
Buy
62.11%
Upside
Reiterated
06/16/25
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning
H.C. Wainwright Analyst forecast on ACLX
Emily BodnarH.C. Wainwright
H.C. Wainwright
$115
Buy
77.55%
Upside
Reiterated
06/16/25
Arcellx Inc's Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
Morgan Stanley Analyst forecast on ACLX
Judah FrommerMorgan Stanley
Morgan Stanley
$111
Buy
71.38%
Upside
Reiterated
06/15/25
Promising Potential of Arcellx Inc's Anito-cel Therapy Drives Buy Rating
Bank of America Securities Analyst forecast on ACLX
Jason GerberryBank of America Securities
Bank of America Securities
$112
Buy
72.92%
Upside
Reiterated
06/13/25
Arcellx Inc's Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential
Canaccord Genuity Analyst forecast on ACLX
John NewmanCanaccord Genuity
Canaccord Genuity
$121
Buy
86.81%
Upside
Reiterated
06/13/25
Arcellx Inc's Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
Evercore ISI Analyst forecast on ACLX
Cory KasimovEvercore ISI
Evercore ISI
$115
Buy
77.55%
Upside
Reiterated
05/15/25
Evercore ISI Sticks to Their Buy Rating for Arcellx Inc (ACLX)
Scotiabank Analyst forecast on ACLX
George FarmerScotiabank
Scotiabank
$93
Buy
43.58%
Upside
Reiterated
05/15/25
Scotiabank Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Truist Financial Analyst forecast on ACLX
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
05/15/25
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Lucid Diagnostics (NASDAQ: LUCD) and Arcellx Inc (NASDAQ: ACLX)
Guggenheim Analyst forecast on ACLX
Unknown AnalystGuggenheim
Not Ranked
Guggenheim
$120
Buy
85.27%
Upside
Reiterated
05/15/25
Anito-Cel’s best-in-class safety profile continues; we remain Buy rated, PT $120.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcellx Inc

1 Month
xxx
Success Rate
15/21 ratings generated profit
71%
Average Return
+6.27%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +6.27% per trade.
3 Months
xxx
Success Rate
13/21 ratings generated profit
62%
Average Return
+13.28%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +13.28% per trade.
1 Year
Jason GerberryBank of America Securities
Success Rate
14/18 ratings generated profit
78%
Average Return
+38.01%
reiterated a buy rating 17 days ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +38.01% per trade.
2 Years
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+33.97%
assigned a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +33.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACLX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
15
16
14
20
26
Buy
17
3
4
7
9
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
19
18
27
35
In the current month, ACLX has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACLX average Analyst price target in the past 3 months is 111.00.
Each month's total comprises the sum of three months' worth of ratings.

ACLX Financial Forecast

ACLX Earnings Forecast

Next quarter’s earnings estimate for ACLX is -$1.02 with a range of -$1.27 to -$0.74. The previous quarter’s EPS was -$1.13. ACLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year ACLX has Outperformed its overall industry.
Next quarter’s earnings estimate for ACLX is -$1.02 with a range of -$1.27 to -$0.74. The previous quarter’s EPS was -$1.13. ACLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year ACLX has Outperformed its overall industry.

ACLX Sales Forecast

Next quarter’s sales forecast for ACLX is $13.52M with a range of $4.00M to $30.00M. The previous quarter’s sales results were $8.13M. ACLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ACLX has Outperformed its overall industry.
Next quarter’s sales forecast for ACLX is $13.52M with a range of $4.00M to $30.00M. The previous quarter’s sales results were $8.13M. ACLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year ACLX has Outperformed its overall industry.

ACLX Stock Forecast FAQ

What is ACLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcellx, Inc.’s 12-month average price target is 111.00.
    What is ACLX’s upside potential, based on the analysts’ average price target?
    Arcellx, Inc. has 71.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACLX a Buy, Sell or Hold?
          Arcellx, Inc. has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Arcellx, Inc.’s price target?
            The average price target for Arcellx, Inc. is 111.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $121.00 ,the lowest forecast is $93.00. The average price target represents 71.38% Increase from the current price of $64.77.
              What do analysts say about Arcellx, Inc.?
              Arcellx, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of ACLX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis